Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

PROF Relative to the S&P 500

PROF Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Profound Medical Corp. (NASD:PROF) seasonal charts above shows that a Buy Date of April 7 and a Sell Date of June 26 has resulted in a geometric average return of 10.54% above the benchmark rate of the S&P 500 Total Return Index over the past 6 years. This seasonal timeframe has shown positive results compared to the benchmark in 5 of those periods. This is a very good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 6 years by an average of 27.37% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 6 years of data is available for shares of PROF, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The firm s product, the TULSA-PRO system, combines real-time MRI, robotically driven transurethral sweeping action/thermal ultrasound, and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It is also focused on developing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. The company was founded on June 13, 2008 and is headquartered in Mississauga, Canada.

To download PROF seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: PROF